Aim: Interstitial lung diseases (ILD) are a group of lung disorders characterized by interstitial lung thickening. Krebs von den Lungen-6 (KL-6) is a molecule that is predominantly expressed by damaged alveolar type II cells and it has been proposed as a potential biomarker of different ILD. Materials & methods: A growing literature about KL-6 has been reviewed and selected to evaluate its role in the clinical management of ILD to predict disease diagnosis, activity, prognosis and treatment response. Results: KL-6 concentrations have been evaluated in fibrotic and granulomatous lung diseases and it was demonstrated to be a biomarker of disease severity useful for clinical follow-up of ILD patients. KL-6 levels differentiated between fibrotic ILD, such as idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis, and nonfibrotic lung disorders, including sarcoidosis and pulmonary alveolar proteinosis. Conclusion: KL-6 is predictive biomarker useful in the clinical management of ILD patients, in particular in patients with severe fibrotic lung disorders.

D'Alessandro, M., Bergantini, L., Cameli, P., Vietri, L., Lanzarone, N., Alonzi, V., et al. (2020). Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review. BIOMARKERS IN MEDICINE [10.2217/bmm-2019-0545].

Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review

d'Alessandro, Miriana;Bergantini, Laura;Cameli, Paolo;Vietri, Lucia;Lanzarone, Nicola;Alonzi, Valerio;Pieroni, Maria;Sestini, Piersante;Bargagli, Elena
2020-01-01

Abstract

Aim: Interstitial lung diseases (ILD) are a group of lung disorders characterized by interstitial lung thickening. Krebs von den Lungen-6 (KL-6) is a molecule that is predominantly expressed by damaged alveolar type II cells and it has been proposed as a potential biomarker of different ILD. Materials & methods: A growing literature about KL-6 has been reviewed and selected to evaluate its role in the clinical management of ILD to predict disease diagnosis, activity, prognosis and treatment response. Results: KL-6 concentrations have been evaluated in fibrotic and granulomatous lung diseases and it was demonstrated to be a biomarker of disease severity useful for clinical follow-up of ILD patients. KL-6 levels differentiated between fibrotic ILD, such as idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis, and nonfibrotic lung disorders, including sarcoidosis and pulmonary alveolar proteinosis. Conclusion: KL-6 is predictive biomarker useful in the clinical management of ILD patients, in particular in patients with severe fibrotic lung disorders.
2020
D'Alessandro, M., Bergantini, L., Cameli, P., Vietri, L., Lanzarone, N., Alonzi, V., et al. (2020). Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review. BIOMARKERS IN MEDICINE [10.2217/bmm-2019-0545].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1113045
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo